Emerging Research Indicates a Crucial Role of IL1RL1 in Exacerbating Inflammation and Infection Risks in Respiratory Ailments

The respiratory tract, a critical battleground for infectious agents, has long been a subject of medical scrutiny. Emerging research is directing a new spotlight on the Interleukin 1 Receptor-Like 1 (IL1RL1), known as suppression of tumorigenicity 2 (ST2)—a key player in immune response regulation. Recently, studies spearheaded by a team including Schaunaman, Sanchez, Dimasuay, Pavelka, Numata, Alam, Martin, and Chu have honed in on the association between IL1RL1 and escalated risks of airway infections and inflammation. Backed by the robust support from numerous NIH grants, their findings have profound implications for individuals with asthma and other respiratory concerns.

The Inflammatory Interplay at the Crossroads of IL1RL1 and IL-33

IL1RL1 acts as a receptor for the cytokine Interleukin 33 (IL-33), an agent known to partake in type 2 immune responses—an arm of the immune system that defends against parasitic infections and is implicated in allergic reactions and asthma. Upon binding IL-33, IL1RL1 has been documented to promote airway inflammation characterized by an increase in eosinophils—a type of white blood cell involved in combating infections and playing a significant role in the manifestations of asthma (Papiris et al., 2002; Jarjour et al., 2012).

Previous studies primarily focused on type 2 inflammation, often linked with causes such as allergens and helminths. However, the role of IL1RL1 in neutrophilic inflammation—a different type characterized by the presence of neutrophils, another variety of white blood cells, has remained largely unexplored. Neutrophilic inflammation frequently correlates with more severe types of asthma and other chronic pulmonary conditions (Wenzel et al., 1999; Panettieri, 2016).

IL1RL1 and Infection Susceptibility: The Mycoplasma pneumoniae Connection

The recent study opens up a new understanding of how IL1RL1 potentially tilts the balance toward increased susceptibility to infections, especially Mycoplasma pneumoniae—a common culprit behind respiratory infections. The research demonstrates how increased signaling through the IL1RL1/IL-33 pathway facilitates bacterial adherence and replication within the airways, thereby exacerbating the infection and inflammation (Martin et al., 2016; Chu et al., 2005; Gally et al., 2011).

Likewise, the study sheds light on the intricate relationship between IL1RL1 and the body’s response to viral infections, with particular attention paid to rhinovirus—the most frequent cause of the common cold and a known instigator of asthma exacerbations (Wark et al., 2013; Gavala et al., 2011).

The Neutrophil Narrative in Neutrophilic Inflammation and IL1RL1

Shifting the paradigm from eosinophilic to neutrophilic inflammation, the research team’s insights suggest that IL1RL1 may have a hand in neutrophil recruitment and activation. This recruitment is particularly noteworthy in the context of respiratory infections where an aggravated neutrophilic response can lead to tissue damage and exacerbation of diseases such as chronic obstructive pulmonary disease (COPD) and severe asthma (Serra-Batlles et al., 1998; Wenzel et al., 1999).

Implications for Asthma Management and Treatment Strategies

The potential of IL1RL1 as a therapeutic target in asthma cannot be overstated. Interventions aimed at modulating the IL1RL1/IL-33 pathway may provide a means to mitigate inflammatory responses and reduce infection risks in patients. This could usher in a new era in the management of severe asthma, which remains a complex and often challenging condition to treat effectively (Moore et al., 2007; Makrinioti et al., 2014).

The Prospect of Personalized Medicine

Personalized treatment strategies tailored according to the type of inflammation—eosinophilic or neutrophilic—could materialize, thereby highlighting the significance of precise immune modulation in combating respiratory ailments (Kraft & Hamid, 2006; Nabe, 2014; Cherry et al., 2008; Tanabe et al., 2014).

Furthermore, this research may also influence the development of biomarkers that could predict infection risk or the course of the inflammatory response in respiratory diseases, offering a proactive approach to management (Cayrol & Girard, 2018; Martin & Martin, 2016; Ali et al., 2009).

The Long Road Ahead: Research and Resistance

Despite the promising horizon, the path to integrating these findings into routine clinical practice is fraught with obstacles. There is a continued need for extensive clinical trials to validate these concepts, determine safety, and address the complexities of modulating immune responses without compromising the body’s defenses (Griesenauer & Paczesny, 2017; Hardman & Ogg, 2016; Mehraj et al., 2016).

Conclusion: Fostering a Future Free from Respiratory Distress

The role of IL1RL1 in promoting airway bacterial and viral infections and inflammation is multifaceted and undoubtedly complex. This emerging body of research is a testament to the continual evolution of our understanding of immune responses and their multifarious interactions with pathogens. As scientists delve deeper into the mechanisms of immune regulation, the goal of a future where infections and inflammation can be preemptively predicted and precisely thwarted appears increasingly attainable.

DOI: 10.1128/IAI.00340-19


1. Papiris S, Kotanidou A, Malagari K, Roussos C. (2002). Clinical review: severe asthma. Crit Care, 6:30–44. doi:10.1186/cc1451.
2. Jarjour NN, Erzurum SC, Bleecker ER, et al. (2012). Severe asthma: lessons learned from the National Heart, Lung, and Blood Institute Severe Asthma Research Program. Am J Respir Crit Care Med, 185:356–362. doi:10.1164/rccm.201107-1317PP.
3. Wenzel SE, Schwartz LB, Langmack EL, et al. (1999). Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med, 160:1001–1008. doi:10.1164/ajrccm.160.3.9812110.
4. Moore WC, Bleecker ER, Curran-Everett D, et al. (2007). Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol, 119:405–413. doi:10.1016/j.jaci.2006.11.639.
5. Panettieri RA Jr. (2016). Neutrophilic and pauci-immune phenotypes in severe asthma. Immunol Allergy Clin North Am, 36:569–579. doi:10.1016/j.iac.2016.03.007.
6. Serra-Batlles J, Plaza V, Morejón E, Comella A, Brugués J. (1998). Costs of asthma according to the degree of severity. Eur Respir J, 12:1322–1326. doi:10.1183/09031936.98.12061322.
7. Kraft M, Hamid Q. (2006). Mycoplasma in severe asthma. J Allergy Clin Immunol, 117:1197–1198. doi:10.1016/j.jaci.2006.03.001.
8. Nabe T. (2014). Interleukin (IL)-33: new therapeutic target for atopic diseases. J Pharmacol Sci, 126:85–91. doi:10.1254/jphs.14R12CP.
9. Gavala ML, Bertics PJ, Gern JE. (2011). Rhinoviruses, allergic inflammation, and asthma. Immunol Rev, 242:69–90. doi:10.1111/j.1600-065X.2011.01031.x.
10. Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. (2008). A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol, 121:1484–1490. doi:10.1016/j.jaci.2008.04.005.
11. Tanabe T, Shimokawaji T, Kanoh S, Rubin BK. (2014). IL-33 stimulates CXCL8/IL-8 secretion in goblet cells but not normally differentiated airway cells. Clin Exp Allergy, 44:540–552. doi:10.1111/cea.12283.
12. Ali M, Zhang G, Thomas WR, et al. (2009). Investigations into the role of ST2 in acute asthma in children. Tissue Antigens, 73:206–212. doi:10.1111/j.1399-0039.2008.01185.x.


1. IL1RL1 and respiratory infection
2. ST2 and inflammation
3. IL1RL1 receptor in asthma
4. Airway inflammation and IL-33
5. Neutrophilic inflammation asthma